Cartalax
Bioregulatory Tripeptide | Cartilage & Connective Tissue Support
Cartalax (AED peptide, T-31) is a synthetic tripeptide consisting of Alanine-Glutamate-Aspartate, developed by Professor Vladimir Khavinson as part of the bioregulatory peptide family. Originally isolated from kidney tissue and found in the alpha-1 chain of type XI collagen, Cartalax has shown potential in supporting cartilage, connective tissue, and cellular regeneration through modulation of proliferation markers and apoptosis pathways.
Daily dose
100-200mcg (1-2 capsules)
Frequency
1-2x daily
Cycle length
1-3 months
Storage
Room temperature
Key benefits
Convenient administration for joint and connective tissue support, used extensively in Russian clinical practice for degenerative conditions with established safety profile.
How it works
Each capsule contains 0.1mg (100mcg) of AC-4 peptide complex. Specialized formulation designed to survive digestion and provide systemic bioregulatory effects.
Dosage protocols
Goal
Standard Protocol
Dose
1 capsule (100mcg) · Daily with meals
Route
Oral
Goal
Intensive Support
Dose
2 capsules (200mcg) · Daily with meals
Route
Oral
Goal
Maintenance
Dose
1 capsule (100mcg) · Every other day with food
Route
Oral
Research indications
joint Health
skin Health
cellular
Administration
Interactions
Safety notes
Take with meals as directed by Russian manufacturers to optimize tolerance
No reported side effects in Russian clinical use when taken properly
Well-tolerated even in elderly patients
Can be combined with conventional treatments
No drug dependence reported
Research studies
Neuronal Differentiation Study (2022)
Periodontal ligament stem cells | 0.1 μg/ml | 7 days | Enhanced differentiation
Cartalax, along with other Khavinson peptides, stimulated proliferation and neurogenic differentiation of stem cells, indicating broader regenerative potential beyond connective tissue.
Bone Marrow Stem Cell Study (2021)
MSCs | 10-100 nM | 14 days | Gene expression changes
Cartalax influenced aging-related gene expression in bone marrow mesenchymal stem cells, potentially maintaining regenerative capacity in both proliferating and stationary phase cells.
Kidney Cell Culture Research (2020)
Renal epithelial cells | Various doses | 7 days | Reduced p53
Demonstrated reduction in pro-apoptotic p53 expression in aging kidney cells, potentially extending cellular lifespan and maintaining tissue integrity through decreased programmed cell death.
Matrix Metalloproteinase Research (2020)
Fibroblast cultures | 20 nM | 5 days | Reduced MMP-9
Inhibited MMP-9 synthesis (associated with tissue breakdown during aging) while maintaining extracellular matrix integrity, suggesting protective effects on connective tissue.
Fibroblast Proliferation Study (2019)
Human skin fibroblasts | 20 nM | 72 hours | Increased Ki-67
Cartalax significantly increased Ki-67 expression (proliferation marker) and CD98hc while suppressing caspase-3 dependent apoptosis in both young and aged fibroblast cultures, suggesting anti-aging effects.
Clinical Spine & Joint Study (Russia)
Human | 0.1mg capsules daily | 1-3 months | Improved mobility
Clinical studies in Russia showed efficacy in comprehensive treatment of spinal osteochondrosis, osteoarthritis, and osteoporosis, with improved joint function and reduced degenerative processes.